When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. What You Need to Know About Prostate Cancer Treatments - AOL

   www.aol.com/know-prostate-cancer-treatments...

   Hormone therapy, also known as androgen deprivation therapy (ADT), is a “mainstay” of treatment for these cancers that have spread outside the prostate, Dr. Barbieri says.

3. Androgen deprivation therapy - Wikipedia

   en.wikipedia.org/wiki/Androgen_deprivation_therapy

   Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

4. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   Hormonal therapy uses medications or surgery to block prostate cancer cells from getting dihydrotestosterone (DHT), a hormone produced in the prostate and required for the growth and spread of most prostate cancer cells. Blocking DHT often causes prostate cancer to stop growing and even shrink.

5. Leuprorelin - Wikipedia

   en.wikipedia.org/wiki/Leuprorelin

   On 24 March 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Camcevi, intended for the treatment of the cancer of the prostate in adult men when the cancer is "hormone-dependent ...

6. What Is Low Testosterone & What Causes It? - AOL

   www.aol.com/low-testosterone-causes-125700734.html

   Cancer treatments. Chemotherapy and radiation therapy can cause permanent problems with testosterone. ... But it may also cause side effects like skin irritation (particularly with gels), a high ...

7. Apalutamide - Wikipedia

   en.wikipedia.org/wiki/Apalutamide

   Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. [8] [9] [10] [15] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer. [2] [10] [9]